-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering Reports Overall Survival Data For Atebimetinib (IMM-1-104) From Ongoing Phase 2a Trial In First-Line Pancreatic Cancer Patients; Says Pivotal Trial Of Atebimetinib In Combination With mGnP In First-line Pancreatic Cancer Patients Planned For 2026

Benzinga·06/17/2025 10:05:00
Listen to the news

Immuneering Corporation, a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced positive data from its ongoing Phase 2a clinical trial evaluating atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.

"These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. "94% overall survival at 6 months is remarkable in first-line pancreatic cancer patients. Atebimetinib was designed to deliver exceptional durability and tolerability to a broad range of patients with different cancers, and it is deeply gratifying to see evidence of that playing out first in one of the most aggressive and deadly types of cancer. Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey."